For how we live.
A test-negative study across seven paediatric hospitals in Ontario and Quebec, run after a publicly funded rollout, estimated 78% effectiveness against laboratory-confirmed RSV and 97% against intensive-care admission.
Positional flat head affects nearly half of two-month-olds and is usually mild. In the one randomised trial, moulding helmets matched the natural course — and every parent reported a side effect.
Bringing up milk is normal in healthy babies: it peaks around four months and usually fades by the first birthday. Most infants need no medicine, and the evidence for acid-suppressing drugs in simple reflux is weak.
The SMART trial tested clesrovimab against palivizumab in premature and heart- and lung-affected infants. It was built to show safety, not to prove one prevents more RSV than the other.
A Buenos Aires surveillance cohort estimates 80.8% effectiveness against RSV hospitalisation in infants under three months — close to what the licensing trial found, in a real programme.